Welcome
Support Centre
22 May 2012 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ ...Back to search results ] [ Print-friendly version ]
A prospective cohort study on incidence and outcome of patients with post-stroke depression in China
ISRCTN ISRCTN62169508
ClinicalTrials.gov identifier
Public title A prospective cohort study on incidence and outcome of patients with post-stroke depression in China
Scientific title
Acronym PRIOD- China
Serial number at source N/A
Study hypothesis 1. Incidence of Post-Stroke Depression (PSD) in China may be different between 3 months and 6 months following onset of stroke
2. Patients with PSD may have poorer outcome than patients without PSD
3. Incidence of PSD may be correlated with stroke subtype, lesion location and other risk factors
Lay summary
Ethics approval Tiantan Hospital Ethics Committee. Date of approval: 12/05/2008
Study design Multi-centre, observational, prospective, nested case-control study.
Countries of recruitment China
Disease/condition/study domain Post-stroke depression
Participants - inclusion criteria 1. New stoke onset
2. Stoke onset time: Within 14d from doctor-visiting date
3. Patients age 18 years or older
4. Sign informed consent, cooperate with examination, and complete follow-ups
Participants - exclusion criteria 1. Unable to complete examination due to the influence of eyesight, hearing, expression, consciousness, and apprehension
2. Stroke patient presenting no sign or symptom
Anticipated start date 10/01/2008
Anticipated end date 01/06/2009
Status of trial Completed
Patient information material Not available in web format, please use the contact details below to request a patient information sheet
Target number of participants 2,500
Interventions 1. The participants are classified into the following groups:
Group A: Stroke inpatients with PSD during follow up at 3 months or 6 months
Group B: Stroke inpatients without PSD during follow up at 3 months or 6 months

2. Diagnostic process & criteria:
2.1. Assessment through scales:
2.1.1. Hamilton Rating Scale for Depression (HRSD). HRSD is used as preliminary screening scale. Trained qualified neurological doctors make standard depression diagnosis of all doctor-visitors with >=8 HRSD scores. Timepoints of assessment: Baseline at 14 days, 3, 6 and 12 months following onset
2.1.2. World Health Organization-Composite International Diagnostic Interview (WHO-CIDI). Trained qualified neurological doctors make standard depression diagnosis of all doctor-visitors with >=8 HRSD scores through CIDI at 3 and 6 months.
2.2. Patient self-assessment scale. Patients assess their mental state through BDI-13 scale biweekly for 3 months and monthly during 3 months - 1 year. Assessment results are recorded in follow-up diary. In case of BDI>=5 during this period, patients should visit hospital for follow-up and CIDI diagnosis by trained qualified neurological doctors.
3. Possible risk factors will be compared between group A and group B, these will include:
3.1. Stroke subtype
3.2. National Institutes of Health Stroke Scale (NIHSS) at 12 months
3.3. Medical history
3.4. Complications
3.5. Lesion location
4. Outcome will be compared between group A and group B, these will include:
4.1 Modified Rankin Scale (mRS) at 3, 6 and 12 months
4.2 Quality of life: Medical Outcome Study Short Form 36 (SF-36) at 12 months
4.3 Stroke recurrence at 3, 6 and 12 months
Primary outcome measure(s) 1. Onset: Incidence of depression within 3 months and 6 months of stoke onset
2. Scale score: Score tendency based on HRSD scale within 14 days, 3 months, 6 months, and 1 year of stoke onset
Secondary outcome measure(s) 1. Quality of life: Medical Outcome Study Short Form 36 (SF-36)
2. mRS score
Sources of funding 1. Wyeth pharmaceuticals
2. Minister of the Science and Technology of the People's Republic of China, National Key Technology R&D Program (ref: 2006BA101A11)
Trial website
Publications
Contact name Prof  Wang  Yongjun
  Address Department of Neurology of Beijing Tiantan Hospital
Capital Medical University
  City/town Beijing
  Zip/Postcode 100050
  Country China
Sponsor Beijing Tian Tan Hospital, Capital Medical University (China)
  Address No.6 Tiantanxili
Chongwen District
  City/town Beijing
  Zip/Postcode 100050
  Country China
Date applied 11/12/2007
Last edited 15/05/2008
Date ISRCTN assigned 21/12/2007
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2012 ISRCTN unless otherwise stated.


BioMed Central